Literature DB >> 35895834

Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice.

Jacqueline M Brady1,2, Meredith Phelps1,3, Scott W MacDonald1, Evan C Lam1, Adam Nitido1,3, Dylan Parsons1, Christine L Boutros1, Cailin E Deal1, Wilfredo F Garcia-Beltran1, Serah Tanno1, Harini Natarajan4, Margaret E Ackerman4,5, Vladimir D Vrbanac1, Alejandro B Balazs1.   

Abstract

HIV broadly neutralizing antibodies (bNAbs) are capable of both blocking viral entry and driving innate immune responses against HIV-infected cells through their Fc region. Vaccination or productive infection results in a polyclonal mixture of class-switched immunoglobulin G (IgG) antibodies composed of four subclasses, each encoding distinct Fc regions that differentially engage innate immune functions. Despite evidence that innate immunity contributes to protection, the relative contribution of individual IgG subclasses is unknown. Here, we used vectored immunoprophylaxis in humanized mice to interrogate the efficacy of individual IgG subclasses during prevention of vaginal HIV transmission by VRC07, a potent CD4-binding site-directed bNAb. We find that VRC07 IgG2, which lacks Fc-mediated functionality, exhibited substantially reduced protection in vivo relative to other subclasses. Low concentrations of highly functional VRC07 IgG1 yielded substantial protection against vaginal challenge, suggesting that interventions capable of eliciting modest titers of functional IgG subclasses may provide meaningful benefit against infection.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35895834      PMCID: PMC9507259          DOI: 10.1126/scitranslmed.abn9662

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   19.319


  44 in total

1.  Fc receptor but not complement binding is important in antibody protection against HIV.

Authors:  Ann J Hessell; Lars Hangartner; Meredith Hunter; Carin E G Havenith; Frank J Beurskens; Joost M Bakker; Caroline M S Lanigan; Gary Landucci; Donald N Forthal; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nature       Date:  2007-09-06       Impact factor: 49.962

2.  Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.

Authors:  Kevin O Saunders; Lingshu Wang; M Gordon Joyce; Zhi-Yong Yang; Alejandro B Balazs; Cheng Cheng; Sung-Youl Ko; Wing-Pui Kong; Rebecca S Rudicell; Ivelin S Georgiev; Lijie Duan; Kathryn E Foulds; Mitzi Donaldson; Ling Xu; Stephen D Schmidt; John-Paul Todd; David Baltimore; Mario Roederer; Ashley T Haase; Peter D Kwong; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2015-08       Impact factor: 5.103

3.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Determination of 50% endpoint titer using a simple formula.

Authors:  Muthannan Andavar Ramakrishnan
Journal:  World J Virol       Date:  2016-05-12

5.  Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques.

Authors:  Matthew S Parsons; Wen Shi Lee; Anne B Kristensen; Thakshila Amarasena; Georges Khoury; Adam K Wheatley; Arnold Reynaldi; Bruce D Wines; P Mark Hogarth; Miles P Davenport; Stephen J Kent
Journal:  J Clin Invest       Date:  2018-11-26       Impact factor: 14.808

6.  A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.

Authors:  Brian Moldt; Mami Shibata-Koyama; Eva G Rakasz; Niccole Schultz; Yutaka Kanda; D Cameron Dunlop; Samantha L Finstad; Chenggang Jin; Gary Landucci; Michael D Alpert; Anne-Sophie Dugast; Paul W H I Parren; Falk Nimmerjahn; David T Evans; Galit Alter; Donald N Forthal; Jörn E Schmitz; Shigeru Iida; Pascal Poignard; David I Watkins; Ann J Hessell; Dennis R Burton
Journal:  J Virol       Date:  2012-03-28       Impact factor: 5.103

7.  Codon usage limitation in the expression of HIV-1 envelope glycoprotein.

Authors:  J Haas; E C Park; B Seed
Journal:  Curr Biol       Date:  1996-03-01       Impact factor: 10.834

8.  Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1.

Authors:  Zhifeng Sun; Paul W Denton; Jacob D Estes; Florence A Othieno; Bangdong L Wei; Anja K Wege; Michael W Melkus; Angela Padgett-Thomas; Mary Zupancic; Ashley T Haase; J Victor Garcia
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

9.  Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission.

Authors:  Alejandro B Balazs; Yong Ouyang; Christin M Hong; Joyce Chen; Steven M Nguyen; Dinesh S Rao; Dong Sung An; David Baltimore
Journal:  Nat Med       Date:  2014-02-09       Impact factor: 53.440

10.  Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.

Authors:  M Sips; M Krykbaeva; T J Diefenbach; M Ghebremichael; B A Bowman; A-S Dugast; A W Boesch; H Streeck; D S Kwon; M E Ackerman; T J Suscovich; P Brouckaert; T W Schacker; G Alter
Journal:  Mucosal Immunol       Date:  2016-02-17       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.